X0202 SCHEDULE 13G 0001952614 XXXXXXXX LIVE Ordinary Shares, par value $0.000000005 per share, (represented by American Depositary Shares) 08/07/2026 0001541157 Akari Therapeutics Plc 00972G405 401 EAST JACKSON STREET SUITE 3300 TAMPA FL 33602 Rule 13d-1(c) White Lion Capital LLC NV 7001638477.00 0.00 7001638477.00 0.00 7001638477.00 5.0 OO With regard to Items 5, 7, and 9: Consists of 7,001,638,477 of ordinary shares, par value $0.000000005 per share, represented by American Depositary Shares. Each American Depositary Share represents 80,000 ordinary shares. Such shares may be issued to the Reporting Person pursuant to an equity line Common Stock Purchase Agreement between the parties pursuant to the determination of the Issuer. With regard to Item 11: Percentage calculated based on 140,032,769,533 ordinary shares outstanding as of June 30, 2026 as reported by the Issuer. Akari Therapeutics Plc 401 EAST JACKSON STREET, SUITE 3300, TAMPA, FLORIDA, 33602. White Lion Capital LLC 17631 Ventura Blvd., Suite 1008 Encino, California 91316 Nevada Y The information contained in rows 5 through and including row 11 on the cover page of this Schedule 13G, including the footnote thereto, is incorporated by reference in this Item 4. The information contained in rows 5 through and including row 11 on the cover page of this Schedule 13G, including the footnote thereto, is incorporated by reference in this Item 4. The information contained in rows 5 through and including row 11 on the cover page of this Schedule 13G, including the footnote thereto, is incorporated by reference in this Item 4. The information contained in rows 5 through and including row 11 on the cover page of this Schedule 13G, including the footnote thereto, is incorporated by reference in this Item 4. The information contained in rows 5 through and including row 11 on the cover page of this Schedule 13G, including the footnote thereto, is incorporated by reference in this Item 4. The information contained in rows 5 through and including row 11 on the cover page of this Schedule 13G, including the footnote thereto, is incorporated by reference in this Item 4. Y N Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. White Lion Capital LLC /s/ Nathan Yee 08/07/2026